Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 83Paclitaxel 71Gemcitabine 66Carboplatin 62Cisplatin 47Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Pemetrexed 29Fluorouracil 29Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Midazolam 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × crenigacestat × Clear all
NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
247 enrolled 53 charts
Lymphoid

Lymphoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡